KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Profit After Tax (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Profit After Tax data on record, last reported at $196.9 million in Q2 2025.

  • For Q2 2025, Profit After Tax rose 2947.86% year-over-year to $196.9 million; the TTM value through Jun 2025 reached -$58.0 million, down 222.54%, while the annual FY2024 figure was $235.2 million, 143.89% up from the prior year.
  • Profit After Tax reached $196.9 million in Q2 2025 per SRPT's latest filing, up from -$447.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $196.9 million in Q2 2025 and bottomed at -$516.8 million in Q1 2023.
  • Average Profit After Tax over 5 years is -$93.0 million, with a median of -$64.8 million recorded in 2021.
  • The widest YoY moves for Profit After Tax: up 2947.86% in 2025, down 1338.98% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$122.0 million in 2021, then increased by 10.44% to -$109.2 million in 2022, then surged by 141.79% to $45.7 million in 2023, then soared by 248.37% to $159.0 million in 2024, then increased by 23.79% to $196.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $196.9 million in Q2 2025, -$447.5 million in Q1 2025, and $159.0 million in Q4 2024.